Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-risk Renal Cell Carcinoma × toripalimab × Clear all
NCT06584435 2025-12-19

TUORA

Tianjin Medical University Second Hospital

Phase 2 Active not recruiting
100 enrolled
Genitourinary

High-risk Renal Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡